Physician profile
George B Plain
NPI 1881629145
$5,660.88
in general payments reported to CMS, 2019-2025
32 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,201 · 2020: $991 · 2021: $1,473 · 2022: $1,142 · 2023: $835 · 2024: $18.29.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $839 · Education: $14.85.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $838.66 |
| Education | $14.85 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,020.35 | 2019-2023 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $964.22 | 2019-2023 | |
| Pfizer INC. | $566.26 | 2019-2023 | |
| Janssen Pharmaceuticals, INC | $327.77 | 2019-2022 | |
| Glaxosmithkline, LLC. | $322.13 | 2019-2023 | Shingrix, Trelegy Ellipta |
| Astellas Pharma US INC | $321.07 | 2019-2023 | Myrbetriq, Veozah |
| Lilly USA, LLC | $292.40 | 2019-2023 | Mounjaro, Trulicity |
| Amgen INC. | $216.90 | 2019-2024 | Evenity, Prolia |
| Boehringer Ingelheim Pharmaceuticals, INC. | $170.30 | 2019-2022 | |
| Astrazeneca Pharmaceuticals LP | $157.86 | 2019-2021 | |
| Merck Sharp & Dohme LLC | $157.80 | 2019-2022 | |
| Abbott Laboratories | $145.04 | 2020-2023 | Freestyle Libre 2, Freestyle Libre 3 |
| Takeda Pharmaceuticals U.S.A., INC. | $130.62 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $104.05 | 2019-2023 | |
| Amarin Pharma, INC. | $85.24 | 2019-2021 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $82.01 | 2019-2020 | |
| Insulet Corporation | $71.97 | 2022-2023 | Omnipod |
| Bayer Healthcare Pharmaceuticals INC. | $68.88 | 2022 | |
| Biohaven Pharmaceuticals, INC. | $56.42 | 2021 | |
| Kowa Pharmaceuticals America, INC. | $56.42 | 2019-2020 | |
| Alkermes, INC. | $55.11 | 2022-2023 | Vivitrol |
| Allergan, INC. | $54.20 | 2019-2020 | |
| Ultragenyx Pharmaceutical INC. | $47.09 | 2020-2021 | |
| Jazz Pharmaceuticals INC. | $42.45 | 2020-2022 | |
| Exact Sciences Corporation | $41.20 | 2023 | Cologuard Collection Kit |
| Smith+Nephew, INC. | $25.29 | 2019 | |
| Biohaven Pharmaceutical Holding Company LTD. | $15.60 | 2022 | |
| Esperion Therapeutics, INC. | $13.76 | 2021 | |
| Boston Scientific Corporation | $13.57 | 2019 | |
| Biogen, INC. | $12.03 | 2022 | |
| Genentech USA, INC. | $11.84 | 2019 | |
| Arbor Pharmaceuticals, INC. | $11.03 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw George Plain listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.